Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PIN1–NRF2 protein-protein interaction is a pivotal regulatory mechanism in the cellular antioxidant defense system and a major contributor to therapeutic resistance in cancer [1, 2]. Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) is a unique enzyme that recognizes phosphorylated serine or threonine residues followed by proline (pSer/Thr-Pro) and catalyzes their cis-trans isomerization, thereby inducing conformational changes in target proteins [1, 3]. In this specific interaction, PIN1 binds to the Nuclear factor erythroid 2-related factor 2 (NRF2), a master transcription factor that orchestrates the expression of numerous antioxidant and detoxifying genes [2, 4]. This isomerization stabilizes NRF2 by interfering with its recognition by E3 ubiquitin ligases, such as the Keap1-independent β-TrCP pathway, thus preventing its proteasomal degradation [4, 5]. High levels of both PIN1 and NRF2 are frequently observed in various cancers, where they cooperate to protect malignant cells from the oxidative stress induced by chemotherapy and radiation [2, 6]. Consequently, disrupting the PIN1–NRF2 axis using PIN1 inhibitors like all-trans retinoic acid (ATRA) or KPT-6566 has emerged as a promising strategy to overcome chemoresistance and enhance the efficacy of standard treatments [5, 6]. However, because PIN1 regulates a wide array of proteins involved in the cell cycle and apoptosis, therapeutic targeting must address potential safety concerns related to systemic toxicity and off-target effects [1, 3]. Sources: [1] UniProt (Q13526, Q16236); [2] Sun, X. et al. (2020) PubMed: 32433614; [3] Zhou, X. Z., & Lu, K. P. (2016) PubMed: 27338439; [4] Liang, J. et al. (2019) PubMed: 31163165; [5] Wei, Z. et al. (2015) PubMed: 26063003; [6] Urbano, A. G. et al. (2019) PubMed: 30861164.
Inhibition of PIN1-mediated prolyl isomerization of NRF2, which prevents NRF2 stabilization and promotes its degradation via the proteasome, thereby increasing cellular sensitivity to oxidative stress and chemotherapy.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1–Nuclear factor erythroid 2-related factor 2 protein-protein interaction (PIN1–NRF2 PPI).